Recap: Mental Health Awareness Month

FDA Approves Onyda XR, First and Only Liquid Nonstimulant for ADHD

Clonidine hydrochloride (Onyda XR) is a once-daily, extended release, oral suspension for treatment of ADHD in pediatric patients aged 6 years and older. Clonidine hydrochloride can be used either as a monotherapy or as an adjunctive therapy to an approved central nervous system stimulant.

Suicide is Second-Leading Cause of Death Among College Athletes

Suicide is among the leading causes of death for National Collegiate Athletic Association (NCAA) athletes, with suicide rates more than doubling over a 20-year study period, according to research published in the British Journal of Sports Medicine.

Mental Health Awareness Month is observed every May. | image credit: Katecat - stock.adobe.com

Psilocybin Treatment for PTSD Shows Positive Topline Results in Phase 2 Study

A single dose of Compass Pathways’ investigational COMP360 was well tolerated and showed durable improvements in CAPS-5 and SDS total scores compared to baseline.

Slideshow: Exercise May Fight Depression, Mindfulness Could Help Reduce Drug Use

With the mental health crisis worsening in the United States, recent research explores novel treatments and underlying causes.

Researchers Announce Positive Efficacy Results for Long-Acting Subcutaneous Olanzapine Injection

The drug, TEV-749, demonstrated statistically significant and clinically meaningful efficacy results.

FDA Approves Oral Treatment for Postpartum Depression

In August 2023, the FDA approved zuranolone (Zurzuvae) for the treatment of adults with postpartum depression (PPD). The drug is the first FDA-approved pill to treat postpartum depression in adults.

READ MORE: Mental and Behavioral Health Resource Center

Are you ready to elevate your pharamcy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips, straight to your inbox.